BerandaEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Tutup sebelumnya
$10,66
Rentang hari
$10,53 - $11,78
Rentang tahun
$2,75 - $13,27
Kapitalisasi pasar
38,16Â jt USD
Volume Rata-Rata
162,24Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 3,14Â jt | -38,31% |
Biaya operasional | 5,43Â jt | 9,83% |
Penghasilan bersih | -4,67Â jt | -36,95% |
Margin laba bersih | -148,85 | -122,00% |
Penghasilan per saham | — | — |
EBITDA | -3,31Â jt | -80,57% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,17Â jt | -73,98% |
Total aset | 20,11Â jt | -24,54% |
Total liabilitas | 11,08Â jt | -20,52% |
Total ekuitas | 9,03 jt | — |
Saham yang beredar | 3,56 jt | — |
Harga terhadap nilai buku | 4,20 | — |
Tingkat pengembalian aset | -44,99% | — |
Tingkat pengembalian modal | -66,40% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -4,67Â jt | -36,95% |
Kas dari operasi | -4,33Â jt | -202,23% |
Kas dari investasi | -126,00Â rb | -500,00% |
Kas dari pembiayaan | 2,92Â jt | 1.030,25% |
Perubahan kas bersih | -1,55Â jt | 13,67% |
Arus kas bebas | -2,43Â jt | -10,05% |
Tentang
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
CEO
Didirikan
2005
Kantor pusat
Situs
Karyawan
50